Public Meeting: Patient-Focused Drug Development for Hemophilia A, B, & Other Bleeding Disorders 1

On September 22, 2014, FDA hosted a public meeting on Patient-Focused Drug Development for Hemophilia A, B, and Other Heritable Bleeding Disorders. FDA was interested in obtaining patient perspectives on the impact of Hemophilia A, B, and Other Heritable Bleeding Disorders on daily life and patient views on treatment approaches. For more information, visit the meeting webpage. https://www.fda.gov/industry/prescrip...